Shopping Cart

No products in the cart.

Frailty

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Frailty is a severe, common co-morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on...
๐Ÿ—“๏ธ 2023-12-29
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEfficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

The burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications

Frailty often coexists with heart failure (HF), which significantly aggravates the clinical outcomes of older adults. However, studies investigating the interplay between frailty and HF in older adults are scarce. We aimed to assess the prevalence of frailty using the...
๐Ÿ—“๏ธ 2024-01-30
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThe burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!